Revitope Oncology and Junshi Biosciences have inked a strategic research collaboration based around Revitope’s protein engineering platform and Junshi's novel antibody components. 14 July 2020
US biotech giant Amgen has announced an additional investment of approximately $421 million in BeiGene's registered direct offering of ordinary shares, which maintains Amgen's current pro rata ownership of BeiGene at approximately 20.3%. 13 July 2020
Shanghai-based Ocumension Therapeutics has raised $184 million through an Initial Public Offering (IPO), listing on the Hong Kong Stock Exchange. 10 July 2020
The US regulator will review a submission from LEO Pharma for approval to market tralokinumab in moderate-to-severe atopic dermatitis (AD). A target action date has been set for the second quarter of 2021. 9 July 2020
Mylan and Fujifilm Kyowa Kirin Biologics today announced that the US Food and Drug Administration has approved Hulio (adalimumab-fkjp), a biosimilar to AbbVie's Humira (adalimumab). 9 July 2020
Concert Pharmaceuticals’ shares were up nearly 18% at $11.76 pre-market today, after it said that the US Food and Drug Administration has granted Breakthrough Therapy designation for its oral Janus kinase inhibitor, CTP-543, for the treatment of moderate-to-severe alopecia areata. 8 July 2020
The European Medicines Agency (EMA) is set to review a bid for breast cancer candidate trastuzumab deruxtecan, an HER2-directed antibody drug conjugate (ADC). 8 July 2020
French drugmaker Sanofi appears keen to mitigate any shock about its pandemic-hit second quarter results, which are due to be presented on July 29. 7 July 2020
Chinese drugmaker and distributor Jiangsu Hengrui Medicine's subsidiary in Shanghai and Hengrui's chairman Sun Piaoyang have formed a new biotech company - Rui Li Di – based in Shanghai. 7 July 2020
UK-incorporated Mylan today announced that the Drug Controller General of India (DCGI) has approved its remdesivir 100mg/vial for restricted emergency use in India as part of the DCGI's accelerated approval process to address urgent, unmet needs amid the evolving coronavirus 2019 (COVID-19) pandemic. 6 July 2020
The World Health Organization (WHO) on Saturday accepted the recommendation from the Solidarity Trial’s International Steering Committee to discontinue the trial’s hydroxychloroquine and lopinavir/ritonavir arms. 4 July 2020
US CNS-focussed drug developer Amylyx Pharmaceuticals today announced it has closed an oversubscribed $30 million Series B financing, led by Morningside Ventures, with participation from other investors. 1 July 2020
Sumitomo Dainippon Pharma Oncology Inc has been formed today through the merger of Tolero Pharmaceuticals and Boston Biomedical, two clinical-stage companies developing novel cancer therapeutics based in the USA and wholly-owned subsidiaries of Japanese drug major Sumitomo Dainippon Pharma. 1 July 2020
The rare diseases business of Italy’s Chiesi has inked a deal with USA-based Bioasis Technologies, related to the latter’s “xB3” platform. 30 June 2020
Swedish Orphan Biovitrum (Sobi) has negotiated a deal with the UK’s National Health Service (NHS), resulting in greater access to Elocta (efmoroctocog alfa) for people with hemophilia A. 26 June 2020
The European Medicines Agency’s human medicines committee (CHMP) has recommended granting a conditional marketing authorization to Veklury (remdesivir) for the treatment of COVID-19 in adults and adolescents from 12 years of age with pneumonia who require supplemental oxygen. 25 June 2020
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
The European Medicines Agency’s pharmacovigilance committee, PRAC, has started a review of medicines containing finasteride and dutasteride following concerns regarding suicidal ideation (suicidal thoughts) and behaviors. 4 October 2024
Opioid Use Disorder (OUD) is a chronic neurological disorder that is described as the consequences associated with repeated, compulsive use of opioid drugs and prolonged self-administration of opioid drugs. 4 October 2024
Proposals from the National Health Service (NHS) England have been set out for a phased launch of Eli Lilly’s obesity injection Mounjaro/Zepbound (tirzepatide) at the start of a consultation. 4 October 2024
Aspire Pharma, a UK-based niche generics business, has announced the acquisition of all assets from Canute Pharma, further expanding its product range. 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
The US Food and Drug Administration (FDA) has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. 3 October 2024
Israel’s Teva Pharmaceutical Industries and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, have announced a global licensing deal for the development of an anti PD-1 oncology biosimilar candidate. 3 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024